相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Three paralogous clusters of the miR-17∼92 family of microRNAs restrain IL-12-mediated immune defense
Xiang Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
The transcription factor RelB restrains group 2 innate lymphoid cells and type 2 immune pathology in vivo
Lei Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Human immunology and immunotherapy: main achievements and challenges
Jezabel Varade et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Immunopathobiology and therapeutic targets related to cytokines in liver diseases
Yong He et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells
Caleb R. Glassman et al.
CELL (2021)
Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10
Robert A. Saxton et al.
SCIENCE (2021)
Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor
Marie Robert et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
MDNA11 is a long-acting IL-2 superkine that potentiates durable immune response in mouse tumor models and non-human primates.
Minh D. To et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Spatial distribution of IL4 controls iNKT cell-DC crosstalk in tumors
Lu Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Esraa M. Eloseily et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
Shinsuke Nakao et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
Heliang Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+T Cell Function and Anti-tumor Immunity
Shanling Shen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
Karin M. Knudson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
Ting Zhou et al.
NATURE (2020)
Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses
Claire Gorby et al.
SCIENCE SIGNALING (2020)
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Tobias Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
Ying Cheng et al.
CANCER BIOLOGY & MEDICINE (2020)
Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells
Sisi Deng et al.
JCI INSIGHT (2020)
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Simona Sivori et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses
Rama Krishna Gurram et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Targeting natural killer cells in solid tumors
Guillaume Habif et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics
Juergen Scheller et al.
TRENDS IN IMMUNOLOGY (2019)
Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
Jian Qiao et al.
CANCER CELL (2019)
A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model
Chuanjian Wu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Treatment of type 2 diabetes with the designer cytokine IC7Fc
Maria Findeisen et al.
NATURE (2019)
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
Patrizia Murer et al.
NEW BIOTECHNOLOGY (2019)
Tissue-resident lymphocytes: from adaptive to innate immunity
Haoyu Sun et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Natural and modified IL-2 for the treatment of cancer and autoimmune diseases
Masayuki Mizui
CLINICAL IMMUNOLOGY (2019)
De novo design of potent and selective mimics of IL-2 and IL-15
Daniel-Adriano Silva et al.
NATURE (2019)
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
Martin Felices et al.
BLOOD ADVANCES (2019)
Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages
Minwoo Kih et al.
BIOMATERIALS (2018)
Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains
Roberto De Luca et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Benjamin Ribba et al.
CLINICAL CANCER RESEARCH (2018)
Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells
Kristina S. Burrack et al.
IMMUNITY (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
Stacy J. Kowalsky et al.
MOLECULAR THERAPY (2018)
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Jonathan T. Sockolosky et al.
SCIENCE (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Tuning the Cytokine Responses: An Update on interleukin (IL)-4 and IL-13 Receptor Complexes
Ilkka S. Junttila
FRONTIERS IN IMMUNOLOGY (2018)
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
Mark R. Albertini et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
Yibo Yin et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Jason M. Redman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA
Achal Achrol et al.
NEURO-ONCOLOGY (2018)
Revisiting IL-2: Biology and therapeutic prospects
Abul K. Abbas et al.
SCIENCE IMMUNOLOGY (2018)
Biology and regulation of IL-2: from molecular mechanisms to human therapy
Rosanne Spolski et al.
NATURE REVIEWS IMMUNOLOGY (2018)
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Dhifaf Sarha et al.
BLOOD ADVANCES (2018)
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents
Sylvia Herter et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer
Xiaoxiao Liu et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
Rodrigo Vazquez-Lombardi et al.
NATURE COMMUNICATIONS (2017)
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Thomas Shum et al.
CANCER DISCOVERY (2017)
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jorg U. Schmohl et al.
CANCER RESEARCH AND TREATMENT (2017)
Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers
Ignacio Moraga et al.
ELIFE (2017)
Cergutuzumab amunaleukin (CEA-IL2v), a CEA- targeted IL-2 variant- based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein et al.
ONCOIMMUNOLOGY (2017)
Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent
Yin Guo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Chunxiao Xu et al.
CLINICAL CANCER RESEARCH (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
Blinatumomab: A novel, bispecific, T-cell engaging antibody
Megan Brafford May et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions
Franziska Bootz et al.
DRUG DISCOVERY TODAY (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
Insights into Cytokine-Receptor Interactions from Cytokine Engineering
Jamie B. Spangler et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
A targeted IL-15 fusion protein with potent anti-tumor activity
Siqi Chen et al.
CANCER BIOLOGY & THERAPY (2015)
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
Riccardo Danielli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ
Yin Guo et al.
JOURNAL OF IMMUNOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Synthetic immunology: modulating the human immune system
Barbara Geering et al.
TRENDS IN BIOTECHNOLOGY (2015)
Remission Induction in a Phase I/II Study of an Anti-CD20-Interleukin-2 Immunocytokine DI-Leu16-IL2 in Patients with Relapsed B-Cell Lymphoma
Veronika Bachanova et al.
BLOOD (2015)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Jiusheng Deng et al.
CANCER RESEARCH (2014)
Toxicity management for patients receiving novel T-cell engaging therapies
David M. Barrett et al.
CURRENT OPINION IN PEDIATRICS (2014)
The IL-2 cytokine family in cancer immunotherapy
Geok Choo Sim et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Side Effects of Cytokines Approved for Therapy
Brian A. Baldo
DRUG SAFETY (2014)
Multifaceted Activities of Type I Interferon Are Revealed by a Receptor Antagonist
Doron Levin et al.
SCIENCE SIGNALING (2014)
Localized Immunotherapy via Liposome-Anchored Anti-CD137+IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
Brandon Kwong et al.
CANCER RESEARCH (2013)
Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
Wenxin Xu et al.
CANCER RESEARCH (2013)
NK cell-based immunotherapy for malignant diseases
Min Cheng et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Michael Kalos et al.
IMMUNITY (2013)
Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours
G. Spitaleri et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
The Immunocytokine L19-IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
Kathrin Schwager et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma
Francesco Papadia et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity
Hing C. Wong et al.
ONCOIMMUNOLOGY (2013)
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram et al.
BLOOD (2012)
IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
Jan Emmerich et al.
CANCER RESEARCH (2012)
The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel
Nadine Pasche et al.
CLINICAL CANCER RESEARCH (2012)
Manipulation of adenovirus interactions with host factors for gene therapy applications
Margaret R. Duffy et al.
NANOMEDICINE (2012)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines
Ilkka S. Junttila et al.
NATURE CHEMICAL BIOLOGY (2012)
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15
Aaron M. Ring et al.
NATURE IMMUNOLOGY (2012)
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
John B. Mumm et al.
CANCER CELL (2011)
Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons
Christoph Thomas et al.
CELL (2011)
IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
Kai-Ping Han et al.
CYTOKINE (2011)
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias
Chen Shochat et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse
Eleonora Mezzaroma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells
John J. O'Shea et al.
SCIENCE (2010)
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
Christoph Schliemann et al.
BLOOD (2009)
The Human Ortholog of Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Fusion Protein Induces Potent Ex vivo Natural Killer Cell Activation and Maturation
Claudia Penafuerte et al.
CANCER RESEARCH (2009)
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
Nicholas D. Huntington et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
An Engineered GM-CSF-CCL2 Fusokine Is a Potent Inhibitor of CCR2-Driven Inflammation As Demonstrated in a Murine Model of Inflammatory Arthritis
Moutih Rafei et al.
JOURNAL OF IMMUNOLOGY (2009)
The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer
Karola Wagner et al.
CLINICAL CANCER RESEARCH (2008)
Preassociation of IL-15 with IL-15Rα-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action
Sigrid Dubois et al.
JOURNAL OF IMMUNOLOGY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2007)
Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseases
Amy D. Brideau-Andersen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Converting IL-15 to a superagonist by binding to soluble IL-15Rα
Mark P. Rubinstein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Targeted delivery of tumor necrosis factor-α to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin
E Balza et al.
CLINICAL CANCER RESEARCH (2006)
TNF-α in cancer treatment:: Molecular insights, antitumor effects, and clinical utility
Remco van Horssen et al.
ONCOLOGIST (2006)
Inquiring into the differential action of interferons (IFNs):: an IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β
DA Jaitin et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ -: Hyperagonist IL-15•IL-15Rα fusion proteins
E Mortier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors
XQ Wang et al.
SCIENCE (2005)
An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma
SD Gillies et al.
BLOOD (2005)
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
R Zeng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy
J Stagg et al.
CANCER RESEARCH (2004)
IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity:: Comparative evaluation of IL-2, IL-15, and IL-21
A Moroz et al.
JOURNAL OF IMMUNOLOGY (2004)
Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis
S Ferrari-Lacraz et al.
JOURNAL OF IMMUNOLOGY (2004)
Selective targeted delivery of TNFα to tumor blood vessels
L Borsi et al.
BLOOD (2003)
Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-Γ secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells
C Heuser et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Interleukin-10 therapy - Review of a new approach
K Asadullah et al.
PHARMACOLOGICAL REVIEWS (2003)
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
A Löffler et al.
LEUKEMIA (2003)
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct
T Dreier et al.
JOURNAL OF IMMUNOLOGY (2003)
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma:: In vivo persistence, migration, and antitumor effect of transferred T cells
C Yee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Inflammatory mediators and the failing heart - Past, present, and the foreseeable future
DL Mann
CIRCULATION RESEARCH (2002)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla et al.
BLOOD (2002)
An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection
S Ferrari-Lacraz et al.
JOURNAL OF IMMUNOLOGY (2001)
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo
AB Shanafelt et al.
NATURE BIOTECHNOLOGY (2000)
Proinflammatory effects of IL-10 during human endotoxemia
FN Lauw et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
